On June 29, HJ Science-B fell 8.12% in regular trading, trading at 40.62 HKD/share, with turnover of HK$4.83 million. The stock continues to face sustained selling pressure since its Hong Kong listing on June 23 at an IPO price of HK$81.80 per share.

The company debuted with a dramatic 56.89% first-day plunge and has since remained in a low-range consolidation pattern, with cumulative losses exceeding 50% from the offering price. As a Chapter 18A clinical-stage biotech firm, HJ Science has no products approved for commercial sale. Its three core candidates — HJ787, HJ178, and HJ891 — remain in clinical development amid intense competitive landscapes. In fiscal 2025, the company reported a net loss of RMB 135 million on minimal revenue of RMB 13 million.

The broader Hang Seng Index has been weakening, with market capital rotating toward AI and high-growth technology sectors, creating systematic selling pressure on unprofitable biotech names and extending the stock's downward adjustment.

HJ Science was founded in 2017 by a team of industry experts and focuses on developing innovative therapies for oncology, autoimmune, and metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)